merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>Significant safety risks, including swelling and bleeding in the brain</answer>
<question_number>2</question_number>
<answer>It might discourage patients from participating in trials for potentially more effective treatments</answer>
<question_number>3</question_number>
<answer>No correlation</answer>
<question_number>4</question_number>
<answer>N/A</answer>
<question_number>5</question_number>
<answer>Patients can potentially stop taking it after amyloid is cleared, reducing overall cost and risk of side effects</answer>
<question_number>6</question_number>
<answer>Patients might be less willing to participate in trials for other treatments</answer>
<question_number>7</question_number>
<answer>Patients can potentially stop treatment after amyloid is cleared, reducing the number of infusions needed</answer>
<question_number>8</question_number>
<answer>Amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>Patients with intermediate tau levels showed slower decline on donanemab than those with high levels</answer>